Carcinogenesis, Vol 18, 2015-2017, Copyright © 1997 by Oxford University Press
LW Wattenberg and RD Estensen
The objective of the present investigation was to determine conditions
under which the synthetic glucocorticoid, budenoside, will inhibit
benzo[a]pyrene (BaP)-induced pulmonary carcinogenesis when administered in
the post-initiation period. For this purpose, female A/J mice were
employed. The animals were given three administrations of 2 mg of BaP by
oral intubation during a 1-week period. Budenoside was fed in the diet
subsequent to the last dose of BaP. Using this format, two experiments were
carried out to determine the effects of varying the time of administration
of budenoside on the magnitude of the inhibition obtained. In both
experiments, one group of mice was fed budenoside (1.5 mg/kg of diet) from
1 week after the last dose of BaP until the termination of the experiment,
15 weeks later. The reduction of pulmonary tumor formation under these
conditions was 89% in the first experiment and 78% in the second (average
84%). In the first experiment the effects of feeding budenoside only during
weeks 1-5 after BaP administration was studied. Under these conditions,
inhibition of pulmonary tumor formation was 35%. In the second experiment,
the effects of postponing the start of feeding budenoside was determined.
In mice in which the budenoside feeding was delayed until 5 weeks after the
last dose of BaP and then continued for the duration of the protocol, a 67%
inhibition of tumor formation was found. The data obtained indicate that
budenoside will produce inhibition of pulmonary adenoma formation when fed
either early or late in the post-initiation stage of carcinogenesis, and
that feeding throughout the entire post- initiation period gives maximum
inhibition.
ARTICLES
Studies of chemopreventive effects of budenoside on benzo[a]pyrene- induced neoplasia of the lung of female A/J mice
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. D'Agostini, L. Mastracci, A. Izzotti, R. Balansky, T. M. Pennisi, V. E. Steele, and S. De Flora Modulation by Phenethyl Isothiocyanate and Budesonide of Molecular and Histopathologic Alterations Induced by Environmental Cigarette Smoke in Mice Cancer Prevention Research, June 1, 2009; 2(6): 546 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Bauer and E. A. Rondini REVIEW PAPER: The Role of Inflammation in Mouse Pulmonary Neoplasia Vet. Pathol., May 1, 2009; 46(3): 369 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Dumstorf, S. Mukhopadhyay, E. Krishnan, B. Haribabu, and W. G. McGregor REV1 Is Implicated in the Development of Carcinogen-Induced Lung Cancer Mol. Cancer Res., February 1, 2009; 7(2): 247 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, L. Tao, R. A. Lubet, V. E. Steele, and M. A. Pereira Modulation by budesonide of a CpG endonuclease in mouse lung tumors Carcinogenesis, July 1, 2007; 28(7): 1499 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.B. Myrdal, K. Karlage, P.J. Kuehl, B.S. Angersbach, B.A. Merrill, and P.D. Wightman Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation Carcinogenesis, May 1, 2007; 28(5): 957 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Balansky, F. D'Agostini, G. Ganchev, A. Izzotti, B. Di Marco, R. A. Lubet, N. Zanesi, C. M. Croce, and S. De Flora Influence of FHIT on benzo[a]pyrene-induced tumors and alopecia in mice: Chemoprevention by budesonide and N-acetylcysteine PNAS, May 16, 2006; 103(20): 7823 - 7828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Lehmler, A. Fortis-Santiago, D. Nauduri, and P. M. Bummer Interaction of long-chain nicotinates with dipalmitoylphosphatidylcholine J. Lipid Res., March 1, 2005; 46(3): 535 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lam, J. C. leRiche, A. McWilliams, C. MacAulay, Y. Dyachkova, E. Szabo, J. Mayo, R. Schellenberg, A. Coldman, E. Hawk, et al. A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium Clin. Cancer Res., October 1, 2004; 10(19): 6502 - 6511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Lubet, Z. Zhang, Y. Wang, and M. You Chemoprevention of Lung Cancer in Transgenic Mice Chest, May 1, 2004; 125(5_suppl): 144S - 147S. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, Z. Zhang, E. Kastens, R. A. Lubet, and M. You Mice with Alterations in Both p53 and Ink4a/Arf Display a Striking Increase in Lung Tumor Multiplicity and Progression: Differential Chemopreventive Effect of Budesonide in Wild-type and Mutant A/J Mice Cancer Res., August 1, 2003; 63(15): 4389 - 4395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Greenberg, J. Hu, S. Basu, J. Hay, J. Reibman, T.-a. Yie, K. M. Tchou-Wong, W. N. Rom, and T. C. Lee Glucocorticoids Inhibit Lung Cancer Cell Growth through Both the Extracellular Signal-Related Kinase Pathway and Cell Cycle Regulators Am. J. Respir. Cell Mol. Biol., September 1, 2002; 27(3): 320 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pereira, Y. Li, W. T. Gunning, P. M. Kramer, F. Al-Yaqoub, R. A. Lubet, V. E. Steele, E. Szabo, and L. Tao Prevention of mouse lung tumors by budesonide and its modulation of biomarkers Carcinogenesis, July 1, 2002; 23(7): 1185 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon, A. J. Dannenberg, W. K. Hong, C. J. Fabian, C. C. Sigman, M. M. Bertagnolli, S. P. Stratton, S. Lam, et al. Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia Clin. Cancer Res., February 1, 2002; 8(2): 314 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Wang, M. Marko, A. R. Dahl, K. S. Engelke, M. E. Placke, A. R. Imondi, J. L. Mulshine, and L. M. De Luca Topical Delivery of 13-cis-Retinoic Acid by Inhalation Up-Regulates Expression of Rodent Lung but not Liver Retinoic Acid Receptors Clin. Cancer Res., September 1, 2000; 6(9): 3636 - 3645. [Abstract] [Full Text]
|
|
|
|
|
|
H. Witschi, D. Uyeminami, D. Moran, and I. Espiritu Chemoprevention of tobacco-smoke lung carcinogenesis in mice after cessation of smoke exposure Carcinogenesis, May 1, 2000; 21(5): 977 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.W. Wattenberg, T.S. Wiedmann, R.D. Estensen, C.L. Zimmerman, A.R. Galbraith, V.E. Steele, and G.J. Kelloff Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol Carcinogenesis, February 1, 2000; 21(2): 179 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jyonouchi, S. Sun, K. Iijima, M. Wang, and S. S. Hecht Effects of anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol Carcinogenesis, January 1, 1999; 20(1): 139 - 145. [Abstract] [Full Text] [PDF]
|
|